# NY-ESO-1 TCR （TAEST16001）for Patients With Advanced NSCLC

> **NCT03029273** · PHASE1 · UNKNOWN · sponsor: **Guangzhou Institute of Respiratory Disease** · enrollment: 20 (estimated)

## Conditions studied

- Lung Cancer, Nonsmall Cell, Recurrent

## Interventions

- **DRUG:** Cyclophosphamide and Fludarabine
- **BIOLOGICAL:** Anti-NY-ESO-1 TCR transduced T cells

## Key facts

- **NCT ID:** NCT03029273
- **Lead sponsor:** Guangzhou Institute of Respiratory Disease
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-03-21
- **Primary completion:** 2019-03
- **Final completion:** 2019-03
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2019-01-17

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03029273

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03029273, "NY-ESO-1 TCR （TAEST16001）for Patients With Advanced NSCLC". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03029273. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*